Search

Bretylium

Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular … The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels.

Eletriptan

Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.

Dronabinol

If not provided in their activated form (such as through synthetic forms like Dronabinol or [DB00486]), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A … From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions.

Measles virus vaccine live attenuated

The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. … Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease.

Futibatinib

[L43347] On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.[L47800] … [A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.

Etonogestrel

[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692] … Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel.

Taurochenodeoxycholic acid

It is also being investigated for its role in inflammation and cancer therapy. … As a medication, taurochenodeoxycholic acid reduces cholesterol formation in the liver, and is likely used as a choleretic to increase the volume of bile secretion from the liver and as a cholagogue to

Inbakicept

[L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … [L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin (

Benzyl alcohol